TW202332682A - 介白素—２３受體之胜肽抑制劑 - Google Patents

介白素—２３受體之胜肽抑制劑 Download PDF

Info

Publication number
TW202332682A
TW202332682A TW111146213A TW111146213A TW202332682A TW 202332682 A TW202332682 A TW 202332682A TW 111146213 A TW111146213 A TW 111146213A TW 111146213 A TW111146213 A TW 111146213A TW 202332682 A TW202332682 A TW 202332682A
Authority
TW
Taiwan
Prior art keywords
nal
aminomethyl
leu
wqc
aminoethoxy
Prior art date
Application number
TW111146213A
Other languages
English (en)
Chinese (zh)
Inventor
亨里克 Ｆ 蒙克
尼爾斯 Ｂ 霍爾姆
拉斯穆斯 萊斯
貝嘉尼 Ｄ 拉森
傑斯帕 Ｍ 馬蒂森
奧克塔夫 卡爾達魯
Original Assignee
丹麥商西蘭製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商西蘭製藥公司 filed Critical 丹麥商西蘭製藥公司
Publication of TW202332682A publication Critical patent/TW202332682A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW111146213A 2021-12-01 2022-12-01 介白素—２３受體之胜肽抑制劑 TW202332682A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21211815.2 2021-12-01
EP21211815 2021-12-01

Publications (1)

Publication Number Publication Date
TW202332682A true TW202332682A (zh) 2023-08-16

Family

ID=78821013

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111146213A TW202332682A (zh) 2021-12-01 2022-12-01 介白素—２３受體之胜肽抑制劑

Country Status (12)

Country Link
US (1) US20250154198A1 (https=)
EP (1) EP4440592A1 (https=)
JP (1) JP2024543204A (https=)
KR (1) KR20240111800A (https=)
CN (1) CN118354781A (https=)
AU (1) AU2022402440A1 (https=)
CA (1) CA3240982A1 (https=)
CL (1) CL2024001598A1 (https=)
IL (1) IL313185A (https=)
MX (1) MX2024006556A (https=)
TW (1) TW202332682A (https=)
WO (1) WO2023099669A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) * 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
MX384213B (es) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
CL2024001598A1 (es) 2024-11-15
IL313185A (en) 2024-07-01
MX2024006556A (es) 2024-06-12
WO2023099669A1 (en) 2023-06-08
CA3240982A1 (en) 2023-06-08
US20250154198A1 (en) 2025-05-15
AU2022402440A1 (en) 2024-05-30
CN118354781A (zh) 2024-07-16
KR20240111800A (ko) 2024-07-17
JP2024543204A (ja) 2024-11-19
EP4440592A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
TW202332682A (zh) 介白素—２３受體之胜肽抑制劑
TW202332683A (zh) 介白素－２３受體之肽抑制劑
JP2023014346A (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
US20240173309A1 (en) Lipidated peptide inhibitors of interleukin-23 receptor
DK2694095T3 (en) COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
TW202406927A (zh) 相對於ｈｒａｓ與ｎｒａｓ具有選擇性之ｋｒａｓ抑制作用的環狀化合物
US20240352073A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
TW202116793A (zh) 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
CN114341161A (zh) 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
CN120019064A (zh) Il-23的环肽抑制剂
JP6143270B2 (ja) マイオスタチン阻害ペプチド
CA2793683A1 (en) Peptidomimetics for modulating interleukin-1 receptor
EP4471049A1 (en) Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) Peptide inhibitors of interleukin-23 receptor
TW202607011A (zh) 介白素－２３受體之胜肽抑制劑
WO2026013260A1 (en) Peptide inhibitors of interleukin-23 receptor
CN121449688A (zh) 白介素-23受体的肽抑制剂及其用途
CN121335914A (zh) 白介素-23受体的肽抑制剂
RU2004103078A (ru) Молекулы иммунного связывания, ингибирующие синцитиальное слияние клеток трофобласта
JP2019023165A (ja) インターロイキン−１８活性阻害剤